We recognize that while preclinical studies have shown that MECOM amplified tumors are sensitive to transcriptional targeted inhibitors in high grade serous ovarian cancer, there is a paucity of data in preclinical models of endometrial cancer. The gene discussed is MECOM; the disease is endometrial cancer.